ArticleBMC biotechnology2026
Comparative analysis of MinION and MiSeq using 16S rRNA gene amplicon sequencing in human gut microbiome.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genetic classification of microbial populations at high taxonomic resolution is crucial for clinical diagnosis and treatment. The classification of complex bacterial communities in the human gut was examined in this study by utilizing amplicon sequencing of the 16S ribosomal RNA (rRNA) gene. The influence of different sequencing platforms and amplicon regions on this classification was investigated. Nineteen human fecal samples were analyzed using both Nanopore MinION and Illumina MiSeq platforms.The main objective of the analysis was to assess how effectively these platforms can characterize gut microbiota at the Amplicon Sequence Variant (ASV), genus, and species levels, taking into account various amplicon regions within the 16S rRNA gene. The findings reveal significant disparities between the two platforms. In particular, the MinION platform demonstrates higher values in terms of ASV and species richness, as well as diversity (both alpha and beta diversity) compared to the MiSeq platform. These variations are dependent on the specific targeted amplicon region of the 16S rRNA gene. However, despite these differences in richness and diversity, there is a notable level of consistency observed in detecting the presence of dominant microbial taxa across both platforms, although their relative abundances varied significantly. Notably, the study emphasizes that the choice of primers used for amplification exerts the most significant impact on the classification results at the genus level, surpassing the influence of the sequencing platform itself. This research provides valuable insights into the strengths and limitations of long-read and short-read sequencing in the context of classifying complex gut microbiota, particularly in clinical microbiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.